The Role of Checkpoint Inhibition in Relapsed/Refractory Pediatric Hepatocellular Carcinoma: Clinical Efficacy and Biologic Correlates - A Phase II Study
Latest Information Update: 31 Jan 2025
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Liver cancer
- Focus Registrational; Therapeutic Use
Most Recent Events
- 28 Jan 2025 Planned End Date changed from 1 Jan 2025 to 1 Jan 2028.
- 28 Jan 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2027.
- 08 Sep 2022 Planned End Date changed from 1 Jan 2023 to 1 Jan 2025.